1. Health technology

  2. •

    Medical specialties
Tecan Group AG

Tecan Group AG

263.80
EUR
+1.00
(+0.38%)
1.74BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
35.37
36.01
38.88
44.01
47.2
50.58
53.8
61.24
77.43
89.98
84.13
73.18
69.69
- -
Basic EPS, GAAP
4.16
3.63
5.05
4.74
5.67
6.02
6.18
8.69
9.95
9.53
10.34
5.3
-8.74
- -
Free Cash Flow per Basic Share
0.74
2.3
7.45
9.08
6.86
5.66
6.33
14
10.64
7.24
9.84
9.23
8.11
- -
Dividend per Share
1.5
1.5
1.49
1.75
1.75
2
2.1
2.2
2.26
2.8
2.9
3
3
- -
Book Value per Share
30.34
32.37
38.43
42.24
47.16
52.05
55.52
61.35
96.61
106.64
105.52
112.79
90.98
90.98
Tangible Book Value per Share
25.96
23.8
28.75
27.97
33.08
34.27
36.74
43.46
6.87
18.04
25.63
28.77
26.78
26.78
Basic Weighted Avg Shares
11
11
11
12
12
12
12
12
12
13
13
13
13
13
Sales/Revenue/Turnover
388
400
440
506
549
594
637
731
947
1,144
1,074
934
882
- -
Operating Margin (%)
14.11
14.32
15.21
13.46
14.63
14.9
13.91
16.67
15.1
12.92
12.66
8.09
5.44
- -
Depreciation Expense
10
10
16
21
25
22
34
38
59
67
71
67
61
- -
Net Income, GAAP
46
40
57
55
66
71
73
104
122
121
132
68
-111
- -
Effective Tax Rate (%)
17.7
18.17
13.42
16.64
16.54
15.23
11.57
12.3
11.79
14.99
1.29
13.56
- -
- -
Profit Margin (%)
11.76
10.07
12.98
10.77
12.02
11.91
11.49
14.19
12.85
10.59
12.29
7.24
-12.54
- -
Working Capital
282
299
355
393
449
433
458
553
365
467
554
325
423
423
LT Debt
2
3
4
10
8
1
34
28
301
293
304
60
208
208
Total Equity
336
361
441
487
550
612
659
734
1,225
1,358
1,349
1,435
1,151
1,151
Return on Invested Capital (%)
13.83
12.87
13.78
11.66
12.31
12.53
11.65
14.1
10.9
7.73
7.96
3.76
- -
- -
Return on Capital (%)
14.41
11.43
14.07
11.59
12.52
12.11
11.25
14.15
10.85
7.64
8.01
4.12
- -
- -
Return on Common Equity (%)
14.5
11.53
14.25
11.75
12.71
12.16
11.51
14.89
12.42
9.38
9.76
4.86
-8.56
- -

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
261
261
10
LT Borrowings
- -
- -
150
LT Finance Leases
60
61
58
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
- -
2,076
1,624

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
856
813
712
Cash, Cash Equivalents & STI
406
397
311
Accounts Receivable, Net
149
125
127
Inventories
230
215
213
Total Current Liabilities
531
506
289
Payables & Accruals
- -
- -
- -
ST Debt
261
261
10
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.75%
12.76%
-19.78%
Free Cash Flow
8.53%
-6.79%
-12.89%
Net Income, GAAP
-21.76%
-57.27%
-263.53%
Sales/Revenue/Turnover
7.93%
5.14%
-5.54%
Total Cash Common Dividend
8.82%
8.18%
-0.76%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,074
2024
- -
- -
- -
- -
934
2025
- -
- -
- -
- -
882

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10.34
2024
- -
- -
- -
- -
5.3
2025
- -
- -
- -
- -
-8.74

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.9
2024
- -
- -
- -
- -
3
2025
- -
- -
- -
- -
3

Company Description

Company Profile APIChatGPT
Address
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business

Company News

Company News APIChatGPT

  • etftrends.com

    How to Invest in AI Drug Discovery

  • seekingalpha.com

    Tecan Group AG (TCGGY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • seekingalpha.com

    Tecan Group AG (TCGGY) Q2 2026 Earnings Call Transcript

  • businesswire.com

    Tecan Accelerates Data-Driven Lab Journey With Agentic AI Developments Powered by NVIDIA

  • globenewswire.com

    Tecan to create Data-Driven Labs with NVIDIA

  • seekingalpha.com

    Tecan Group AG (TCGGY) Analyst/Investor Day Transcript

  • seekingalpha.com

    Tecan Group AG (TCGGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

  • businesswire.com

    Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q's Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q2 2024 Earnings Call Transcript

  • globenewswire.com

    Tecan appoints Mukta Acharya Head of the Life Sciences Business division

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q4 2023 Earnings Call Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q2 2023 Earnings Call Transcript